Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

PALACROS Prioritising multimodal surgical care for patients with locally advanced pancreatic cancer across Europe

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 July 2026 to 30 June 2032
Status
Running
EU funding
€10.0m
Total cost
€10.6m
Partners
22 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101288659

What the project is doing

In the project's own words, from its summary on CORDIS.

This action is part of the Cancer Mission cluster of projects on “Diagnosis and Treatment-Innovative Surgery”. BACKGROUND: Pancreatic cancer is the deadliest solid tumour in Europe, with a 5-year survival of 13%. Locally advanced pancreatic cancer (LAPC) affects >50,000 Europeans annually and is essentially fatal without surgery. In recent years, expert centres have doubled their LAPC-resection rates up to 20% through novel multimodal systemic therapy and surgical techniques.

However, randomised trials confirming the benefit of this approach are lacking. In most European countries max 5% of patients with LAPC undergo resection. This inequity translates into survival gaps of 20% between countries, making LAPC one of the clearest examples of cancer inequality in Europe. AIM: PALACROS will optimise surgery-centred multimodal LAPC-treatment across Europe through training and (randomised) trials.

APPROACH: PALACROS will roll out a pan-European training programme in six mentee countries, doubling surgical resection rates. For durable improvement also in non-expert centres, patient selection will be optimised by developing harmonised eligibility criteria supported by AI-based identification of candidates for LAPC-resection via imaging. Outcome collection is optimised through a Core Outcome Set co-designed with patients including survival, quality of life, and cost-effectiveness.

We will perform the first international RCT comparing surgery with MRI-guided stereotactic body radiotherapy after induction chemotherapy to deliver strong evidence of benefit of the multimodal surgical approach in LAPC. This is complemented by two trials on innovative intratumoural therapies. A GDPR/EHDS-compliant federated data and biobank platform will secure sustainability. IMPACT: PALACROS will double LAPC resection rates from <5% to 10% in at least 6 European countries, extending median survival by 6 months and improving quality of life for thousands of patients.

It will provide level-1 evidence to update guidelines, reimbursement, and cancer plans, while embedding training, equity, and patient voices.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Biobanks and Biomolecular Resources Research Infrastructure Consortium (bbmri-Eric)GrazAustriaParticipant
Kepler Universitatsklinikum GmbHLinzAustriaParticipant
Medizinische Universitaet WienWienAustriaParticipant
United European Gastroenterology GmbHViennaAustriaParticipant
Pancreatic Cancer EuropeBruxelles / BrusselBelgiumParticipant
Oncosil Medical Europe GmbHBerlinGermanyParticipant
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyThird party
Region HovedstadenHillerodDenmarkParticipant
Universita Degli Studi Di PadovaPadovaItalyParticipant
Universita Degli Studi Di VeronaVeronaItalyParticipant
Universita Di PisaPisaItalyParticipant
Vilniaus UniversitetasVilniusLithuaniaParticipant
Oncolize BVMaastrichtNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Oslo Universitetssykehus HfOsloNorwayParticipant
Slaski Uniwersytet Medyczny W KatowicachKatowicePolandParticipant
Institutul Clinic FundeniBucurestiRomaniaParticipant
Collective Minds Radiology ABDanderydSwedenParticipant
Region StockholmStockholmSwedenParticipant
University Hospital Birmingham Nhs Foundation TrustBirminghamUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI